Zhifei biotech selects Viedoc in 40 000 subject Phase III COVID-19 vaccine trial

Stockholm – November 24, 2020 – Viedoc, the world's fastest-growing eClinical suite, announced today its collaboration with Anhui Zhifei Longcom Biopharmaceutical Co., Ltd, China, to support its phase III clinical trial COVID-19 vaccine candidate.

Viedoc's suite of technologies has been chosen to support the advancement of Zhifei Biotech's large phase III 7754801_ COVID-19 clinical trial expected to enroll 40,000 participants. This global study will span the Asian, Middle Eastern/African, European, and American continents and is moving ahead with an urgency made necessary by the global pandemic. Using the Viedoc cloud-based eClinical suite is enabling this study to proceed at unheard-of speeds.

Recently, data results of the safety and immunogenicity in Phase I and II clinical trials completed by Zhifei Biotechnology have been analyzed. The Phase I and Phase II clinical data of Zhifei Biorecombinant Protein Covid-19 Vaccine will soon be disclosed in academic journals such as The Lancet. The data proves the recombinant new coronavirus vaccine (CHO cells) has good safety levels, meeting the clinical trial protocol. These approvals allow for immunogenicity, the next clinical trial, to be launched.

"We are proud to be working with Zhifei Biotechnology on critically important trials such as this, which are vital, not only to medical science but to the health of our global community," said Henrik Blombergsson, co-founder and COO of Viedoc Technologies. "This new partnership we've formed will allow us to accelerate the research of this critical clinical study. Trials like these are the very reason we have offered reduced rates in COVID-19 research. Obviously, the faster we can help Zhifei complete their vital Phase III, the better it will be for the health of the world."

Zhifei Biotechnology is pleased to collaborate with Viedoc. "Viedoc's unified eClinical suite is a critical component in the success of our efforts to develop a safe and effective vaccine against COVID-19."

Zhifei Biotechnology is using the Viedoc eClinical suite to help support and accelerate clinical development. The suite includes Viedoc Clinic (the core of the EDC system), Viedoc Admin for easy administration of sites and staff. Additional features can also include, ViedocMe (patient diary and outcomes assessment), Viedoc Logistics including randomization, and eLearning among many others. Zhifei Biotechnology has recently formed a partnership with Viedoc Technologies to help increase the speed and accuracy of their clinical trials.

Viedoc Technologies is a dedicated developer of eClinical systems. The company was founded in Sweden in 2003 by people from the Life Science industry. Today, its clients are clinical research organizations, pharmaceutical, medical device companies, and research institutions that work to enhance the lives of millions of people around the world every day.